Angiotensin-induced metabolic dysfunction

Journal of Hypertension

Volumn 27, Issue 3, 2009, Pages 658-659

  Thornton, Simon Nigel ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ATRIAL NATRIURETIC FACTOR; GLUCOSE;

BLOOD PRESSURE REGULATION; DISEASE MODEL; GLUCOSE TRANSPORT; HEART FAILURE; HORMONE ACTION; HUMAN; HYPERTENSION; HYPOVOLEMIA; LETTER; METABOLIC DISORDER; NONHUMAN; OBESITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 67649565529     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32831940f4     Document Type: Letter

References (18)

1. Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26:831-843.
2. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38:884-890.
3. Izawa Y, Yoshizumi M, Fujita Y, Ali N, Kanematsu Y, Ishizawa K, et al. ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells. Exp Cell Res 2005; 308:291-299.
4. Roberge C, Carpentier AC, Langlois MF, Baillargeon JP, Ardilouze JL, Maheux P, Gallo-Payet N. Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. Am J Physiol Endocrinol Metab 2007; 293:E1465-E1478.
5. Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 2008; 51:1252-1258.
6. Rizzoni D, Pasini E, Flati V, Rodella LF, Paiardi S, Assanelli D, et al. Angiotensin receptor blockers improve insulin signaling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats. J Hypertens 2008; 26:1595-1601.
7. Henriksen EJ. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007; 293:R974-R980.
8. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008; 10:1713-1765.
9. Corbould A. Effects of spironolactone on glucose transport and interleukin-6 secretion in adipose cells of women. Horm Metab Res 2007; 39:915-918.
10. Mihailidou AS, Bundgaard H, Mardini M, Hansen PS, Kjeldsen K, Rasmussen HH. Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na(+)-K(+) pump. Circ Res 2000; 86:37-42.
11. Mihailidou AS, Mardini M, Funder JW, Raison M. Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia. Hypertension 2002; 40:124-129.
12. Ruskoaho H, Lang RE, Toth M, Ganten D, Unger T. Release and regulation of atrial natriuretic peptide (ANP). Eur Heart J 1987; 8 (Suppl B):99-109.
13. Thornton SN, Baldwin BA. Centrally injected atrial natriuretic factor inhibits angiotensin- and osmotically-induced drinking in pigs. Q J Exp Physiol 1988; 73:1009-1012.
14. Yun AJ, Lee PY, Bazar KA. Clinical benefits of hydration and volume expansion in a wide range of illnesses may be attributable to reduction of sympatho-vagal ratio. Med Hypotheses 2005; 64:646-650.
15. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci 2006; 7:335-346.
16. Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007; 25:909-920.
17. Fitzsimons JT. Angiotensin, thirst, and sodium appetite. Physiol Rev 1998; 78:583-686.
18. Schliess F, Häussinger D. Cell volume and insulin signaling. Int Rev Cytol 2003; 225:187-228.